1.
Lancet Infect Dis
; 19(5): 558, 2019 05.
Article
in English
| MEDLINE
| ID: mdl-31034399
Subject(s)
Actinomycosis/diagnosis , Esophageal Neoplasms/diagnosis , Actinomyces/drug effects , Actinomyces/isolation & purification , Actinomycosis/drug therapy , Actinomycosis/microbiology , Actinomycosis/pathology , Aged , Anti-Bacterial Agents/therapeutic use , Diagnosis, Differential , Esophageal Neoplasms/microbiology , Esophageal Neoplasms/pathology , Esophagus/microbiology , Esophagus/pathology , Female , Humans , Treatment Outcome
2.
Case Rep Oncol
; 6(1): 45-9, 2013 Jan.
Article
in English
| MEDLINE
| ID: mdl-23466981
ABSTRACT
Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy. In addition to the possible mutagenic effect of temozolomide - as described for all alkylating agents - there might have been an immunosuppressive effect of TMZ. The pathological appearance of the lymphoma as well as the presence of a grade 3 lymphopenia early in treatment supports this hypothesis. As the use of TMZ increases, the awareness that TMZ may induce secondary malignancies should increase as well.